BIXLENVO (Bictegravir Sodium; Lenacapavir Sodium) Patent Expiration, LOE Window & CMS Spending

BIXLENVO (Bictegravir Sodium; Lenacapavir Sodium) by Gilead Sciences: FDA Orange Book core substance LOE 2038-08-16, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $4,595 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN221104 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-08-16
Last Listed Patent or Exclusivity Date2038-08-16
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,595 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.